OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Two Hematological Markers Predicting the Efficacy and Prognosis of Neoadjuvant Chemotherapy Using Lobaplatin Against Triple-Negative Breast Cancer
Cheng Wang, Qiyun Shi, Guozhi Zhang, et al.
The Oncologist (2024) Vol. 29, Iss. 5, pp. e635-e642
Open Access | Times Cited: 6
Cheng Wang, Qiyun Shi, Guozhi Zhang, et al.
The Oncologist (2024) Vol. 29, Iss. 5, pp. e635-e642
Open Access | Times Cited: 6
Showing 6 citing articles:
Pretreatment System Inflammation Response Index (SIRI) is a Valuable Marker for Evaluating the Efficacy of Neoadjuvant Therapy in Breast Cancer Patients
Yunuo Zhang, Jingna Wu, Weiming Chen, et al.
International Journal of General Medicine (2024) Vol. Volume 17, pp. 4359-4368
Open Access | Times Cited: 4
Yunuo Zhang, Jingna Wu, Weiming Chen, et al.
International Journal of General Medicine (2024) Vol. Volume 17, pp. 4359-4368
Open Access | Times Cited: 4
The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy
Sedat Yıldırım, Akif Doğan, Goncagül Akdağ, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Sedat Yıldırım, Akif Doğan, Goncagül Akdağ, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase II study
Cheng Wang, Long Yuan, Xiujuan Wu, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 3
Cheng Wang, Long Yuan, Xiujuan Wu, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 3
EP300 promotes tumor stemness via epigenetic activation of CRISP3 leading to lobaplatin resistance in triple-negative breast cancer
Yan Wang, Y M Zhang, Xiaowei Qi
Human Cell (2024) Vol. 37, Iss. 5, pp. 1475-1488
Closed Access | Times Cited: 2
Yan Wang, Y M Zhang, Xiaowei Qi
Human Cell (2024) Vol. 37, Iss. 5, pp. 1475-1488
Closed Access | Times Cited: 2
Comparison of the effectiveness of neoadjuvant chemotherapy and adjuvant chemotherapy for improving prognosis in triple-negative breast cancer patients
W. Li, Yu-Wei Chang, Xiaohui Bai, et al.
American Journal of Translational Research (2024) Vol. 16, Iss. 8, pp. 3978-3989
Open Access
W. Li, Yu-Wei Chang, Xiaohui Bai, et al.
American Journal of Translational Research (2024) Vol. 16, Iss. 8, pp. 3978-3989
Open Access
Enhancing lobaplatin sensitivity in lung adenocarcinoma through inhibiting LDHA-targeted metabolic pathways
Siyu Yuan, Wenjie Ou, Xuguang Mi, et al.
PLoS ONE (2024) Vol. 19, Iss. 12, pp. e0310825-e0310825
Open Access
Siyu Yuan, Wenjie Ou, Xuguang Mi, et al.
PLoS ONE (2024) Vol. 19, Iss. 12, pp. e0310825-e0310825
Open Access
